A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

MLA

Wagner, Andrew J., et al. “A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 19, no. 21, Nov. 2013, pp. 6020–29. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-13-0953.

APA

Wagner, A. J., Chugh, R., Rosen, L. S., Morgan, J. A., George, S., Gordon, M., Dunbar, J., Normant, E., Grayzel, D., & Demetri, G. D. (2013). A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(21), 6020–6029. https://doi.org/10.1158/1078-0432.CCR-13-0953

Chicago

Wagner, Andrew J, Rashmi Chugh, Lee S Rosen, Jeffrey A Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, and George D Demetri. 2013. “A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 19 (21): 6020–29. doi:10.1158/1078-0432.CCR-13-0953.